Decitabine priming enhances selinexor antileukemic effects in vivo. (A) Survival curve of NSG mice injected with MV4-11 xenografts and treated with indicated drugs. Survival comparison was made with a log-rank test. (B) Patients’ primary AML blasts were treated with DAC for 16 hours followed by selinexor for 24 hours. Controls included dimethylsulfoxide (DMSO), DAC alone, and selinexor treatments alone. Cell viability was measured by using Annexin V/propidium iodide (PI) staining, and DMSO treated cells were normalized to 100% for comparison between treatment groups.